GOG-F

ENGOT-OV24 / NSGO-AVANOVA2

Niraparib and niraparib-bevacizumab combination against bevacizumab alone in Women with Homologous Recombination Deficient (HRD) platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. 

Trial Number
NCT02354131 (ClinicalTrials.gov Identifier)
Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number

Imagyn

A phase 3 multicenter randomized staudy of Atezolizumab vs placebo administered in combination with Paclitaxel,Carboplatin and Bevacizumab to patients with newly diagnosed stage III or stage IV ovarian, fallopian tube or primary peritoneal cancer

Trial Number
NCT03038100 (ClinicalTrials.gov Identifier)
Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number

BEATcc/ ENGOT-Cx10/ GEICO 68-C/ JGOG1084/ GOG-3030

A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and Bevacizumab in Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cervix 

Trial Number
NCT03556839 (ClinicalTrials.gov ID)
Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number

EORTC 62113-55115

A Randomized Double-blind Phase II Study Evaluating the Role of Maintenance Therapy With Cabozantinib in High Grade Undifferentiated Uterine Sarcoma (HGUS) After Stabilization or Response to Doxorubicin +/- Ifosfamide Following Surgery or in Metastatic First Line Treatment

Trial Number
NCT01979393 (ClinicalTrials.gov Identifier)
Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number

ENGOT-EN20/GOG-3083/XPORT-EC-042

A Phase 3, Randomized, Placebo-Controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced or recurrent endometrial carcinoma

Trial Number
2022-02540-42 (EudraCT Number)
Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number

ENGOT-EN11/GOG-3053/KEYNOTE-B21

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus placebo in combination with adjuvant chemotherapy with or without radiotherapy for the treatment of newly diagnosed High-Risk Endometrial Cancer after surgery with curative Intent

Trial Number
2020-003424-17 (EudraCT Number)
Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number

ENGOT-ov50/GOG-3029/INNOVATE-3

Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer

Trial Number
NCT03940196
Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number

ENGOT-ov43/GOG-3036/MK-7339

A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) 

Trial Number
NCT03740165
Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number
Subscribe to GOG-F